ABSTRACT

The present investigation aims at assessing the hepatoprotective effect of triterpene fraction isolated from the stem bark of *Wrightia tinctoria* (containing lupeol, β-amyrin and β-sitosterol) on CCl₄-induced hepatotoxicity in the rat. CCl₄ (1.5 mg/kg, i.p.) is a potent hepatotoxic agent which causes peroxidative degeneration of membrane lipids with the potential outcome of fatty degeneration. The peroxidative products induce hypoperfusion of the membrane and cytosolic enzymes appear in the blood, elevation of serum marker enzymes namely SGPT, SGOT and ALP and decrease in hepatic glutathione and SOD. The hepatoprotection of triterpene is compared with silymarin, a well known standard hepatoprotectant. Pretreatment with triterpene fraction (125, 250 and 400 mg/kg, p.o. once a day for 4 days before CCl₄ and continued further 3 days) attenuated the CCl₄-induced acute increase in serum SGPT, SGOT and ALP activities and considerably reduced the histopathological alterations. Further, triterpene fraction reduced thiopentone-induced sleeping time, suggesting the protection of liver metabolizing enzymes. Triterpenes administration changed the tissue redox system by scavenging the free radicals and by improving the antioxidant status of the liver replenished the depleted hepatic GSH and SOD. Triterpene pretreatment improved bromosulphalalin clearance of the CCl₄-intoxicated liver and also increases the cellular viability. These effects substantiates protection of cellular phospholipid from peroxidative damage induced by highly reactive toxic intermediate radicals formed during biotransformation of CCl₄. Triterpene fraction afforded protection against the hepatic abnormalities due to presence of lupeol and β-amyrin. This study supports the traditional use of *W. Tinctoria* bark in liver diseases.

Keywords: *Wrightia tinctoria*, Triterpene, Lupeol, β-amyrin, Hepatoprotective
Triacontanol and tryptanthrin have been isolated from *W. tinctoria* leaves [13]. The mature powdered pods of *W. tinctoria* show co-occurrence of β-amyrin, ursolic acid and oleanolic acid along with β-sitosterol [14]. Methanol extract of the immature seedpods contains cycloartenone, β-amyrin, cycloeucalenol and β-sitosterol and fifth one was identified as wrightial, a new terpene [15]. A new sterol 14α-methylzymosterol in addition to four rare plant sterols, desmosterol, clerosterol, 24-methylene-25-methylcholesterol and 24-dehydropollinastanol have been isolated from *W. tinctoria* seeds [16]. The stem bark of *W. tinctoria* contains β-amyrin, lupeol, β-sitosterol and a new triterpenoid [17]. Triterpenes are biologically active secondary plant substances that display antimicrobial, hepatoprotective and anti-inflammatory effects [2]. Traditionally *W. tinctoria* is used in bilious affections and jaundice, phytopharmacological effect on liver disorder is not reported. The present study was taken up with the aim of assessing hepatoprotective activity of the purified and enriched triterpenoidal fraction of *W. tinctoria* bark.

**MATERIALS AND METHODS**

**Plant material**

*W. tinctoria* bark was collected from Hoshangabad district of Madhya Pradesh, India September 2004. The plant was identified with the help of available literature and authenticated by Dr. A. P., Shrivastava, Principal, P K S Govt. Ayurveda College and Institute, Bhopal, India. A voucher specimen was deposited in the herbarium of department (Herbarium No. Bigoniya 1084).

**Isolation and purification of W. tinctoria bark triterpenoidal fraction**

Air dried, powdered bark was exhausted by cold percolation with petroleum ether. The percolate was evaporated under 40°C up to 1/10 of initial volume, a colourless crystalline solid deposited. The supernatant liquor was decanted and concentrated to 1/4 volume, which again deposited a very sticky and rubbery material. The clear supernatant was decanted and completely evaporated using a rotary vacuum evaporator (Superfit, India). Refluxing on a water bath with benzene and N/10 alchoholic potassium hydroxide for 15 hours saponified this residue. The solvents were removed under reduced pressure, washed with large amount of water, which separates a bulky solid, filtered and dried (unsaponifiable matter, yield 1.28%). This was crystallized alternatively from petroleum ether and alcohol repeatedly which eliminates most of the sticky material (pale yellow crystals, yield 0.65%). This crystalline material was extracted with boiling methanol and insoluble sterol fraction gives following color reactions described in the literature for triterpenes: in Salkowski reaction yellow colour in the sulphuric acid layer, in Hasse’s test brown precipitate changing to yellow, in Noller’s test with thionyl chloride containing 0.01% anhydrous stannic chloride gives reddish-violet colour changing to purple, in the Liebermann-Burchard test violet colour [18]. The resulting highly purified triterpene fraction (TF) in the form of dry crystals contains lupeol and β-amyrin as the major compound, along with β-sitosterol and other triterpene. The triterpene fraction on application of suitable fractionation technique yields β-amyrin acetate (yield 0.03%; m.p. 238-40°C), lupeol benzoate (yield 0.028%; m.p. 266-70°C) and β-sitosterol (yield 0.004%; m.p. 132-34°C). All these was authenticated by co-TLC with authentic samples of lupeol, β-amyrin and β-sitosterol in petroleum ether:benzene:chloroform (1:1:1) solvent system. The identity has been established by colour reactions, elementary analysis, optical rotation and mixed melting point with authentic sample [17].

**Experimental Animals**

Laboratory-bred Wister albino rats of both sexes (150 – 200 g) maintained under standard laboratory conditions at 22 ± 2°C, relative humidity 50 ± 5% and photoperiod (12-h dark and light), were used for the experiment. Commercial pellet diet (Hindustan Lever, India) and water were provided *ad libitum*. Experimental protocol was approved by the Institutional Animal Ethical Committee (approved body of Committee for the Purpose of Control and Supervision of Experiments on Animals, Chenni, India) of Dr. H.S. Gour University, Sagar, India and care provided to the animal was as per the WHO ‘guidelines for the care and use of animals in scientific research’.

**Determination of LD<sub>50</sub>**

Acute oral toxicity of the triterpenoid fraction was determined following the acute toxicity class method (OECD guideline No. 423) and revised Up & Down method (OECD guideline No. 425). A Limit test was performed to categorize the toxicity class of the compound and then Main test was performed to estimate the exact LD<sub>50</sub>. The animals (nulliparous and non-pregnant female Wistar albino rats) were fasted overnight with free access to water, weighed and a single dose of the test substance was administered. Animals were observed individually during first 30 minutes, periodically during 48 hours with special attention given during first 4 hours (short-term toxicity) and daily thereafter for total of 14 days (short-term toxicity). The limit test was started from 2000 mg/kg dose. LD<sub>50</sub> was found greater then the test dose so the test substance could be classified in the hazard classification as class 5, 2000 mg/kg<LD<sub>50</sub><5000 mg/kg in the Globally Harmonized System (GSH). LD<sub>50</sub> of the triterpenoid fraction was found to 3165.25 mg/kg from
**Hepatoprotective activity study**

In view of multiplicity and complexity of the liver functions, it is obvious that no single test can establish the disturbances in liver function. Thus, a battery of liver function test was employed for accurate diagnosis, to assess the severity of damage, to judge prognosis and to evaluate therapy.

The rats were divided into six groups of six animals each. Animals of group I- vehicle control, group II-negligible control (Carbon tetrachloride, 1.5 mg/kg, i.p.), group III- silymerin (20 mg/kg), group IV, V and VI were administered *W. tinctoria* triterpinoidal fraction (WTTF) at a dose of 125, 250 and 400 mg/kg, p.o. respectively. Vehicle used for WTTF was propylene glycol and Tween 80 in 4:1 ratio. All the animals of group I, III and IVth to IXth were treated with different doses of vehicle, silymerin and WTTF for four days. On 4th day 2 hrs after drug administration all animals including group II were treated with CCl<sub>4</sub> in liquid paraffin (1:1) in a dose of 1.5 ml/kg i.p. Drug treatment schedule was repeated for further three days. All the hepatoprotective parameters were assessed on last day (7th day) 2 hours after drug administration.

**Thiopentone-induced sleeping time**

Sleeping induced by short acting barbiturate is significantly prolonged in the event of any hepatic damage and this can be used as a measure of the function of the drug metabolizing enzymes. On 7th day a single dose of thiopentone (4 mg/kg, i.p.) was given to the animals and the time between loss of the righting reflex and its recovery was taken as duration of thiopentone induced sleeping time [20].

**Effect on serum biochemical parameters**

On 7th day of treatment, all the animals were sacrificed to collect liver and blood samples. Blood samples were centrifuged at 3000 rpm for 5 minutes, serum was collected and analyzed for estimation of biochemical parameters, i.e. alkaline phosphatase [21], glutamate pyruvate transaminase and glutamate oxaloacetate transaminases [22], total and direct bilirubin [23], total protein [24], albumin [25], cholesterol [26] and triglyceride [27].

**Estimation of free radical scavenging ability of liver**

Free radical-mediated cell injury plays an important role in chemical induced hepatotoxicity. Liver tissues excised, weighed, homogenized and supernatent used for estimation of free radical scavenging ability. Glutathione reduces H<sub>2</sub>O<sub>2</sub> directly to water or react directly with the free radicals such as •O<sub>2</sub>, •OH, •O<sub>H</sub> by a radical transfer process, which yields thiol radicals. This thiol radical presents in glutathione forms a colored complex with DTNB which is measured colorimetrically at 412 nm [28]. Lipid peroxidative degradation of biomembranes is one of the principal causes of hepatotoxicity of CCl<sub>4</sub> [29]. Thiobarbituric acid reactive substance of lipid peroxidation (malondialdehyde) was determined following the method of Okhawa et. al. [30]. Superoxide dismutase was estimated as per the method of Misra and Fridovich [31].

**Histopathological Studies of liver**

The isolated liver slices were fixed in Aqua Bouin’s fluid and processed for histopathological assessment of liver damage following method of Nanji et al. [32].

**Viability study of liver cells**

Loss of cell viability is most often measured as loss of membrane integrity. This event may be primarily due to necrosis or secondarily due to apoptosis. Trypan blue exclusion is a cell viability assay based on the ability of the liver cells to exclude the trypan blue and uptake of the dye by the dead cells due to alteration in the membrane permeability. Viability was measured by trypan blue exclusion test following the method of William et. al. [33].

**Bromosulphthalein uptake test**

It is generally agreed that in the passage of bromosulphthalein (BSP) from the plasma to the bile, it undergoes storage, metabolism, and excretion by the liver. It is well documented that CCl<sub>4</sub> produces morphological and functional changes in the liver. Bromosulphthalein clearance test is the most sensitive and dependable method to assess the physiological status of liver function. The test indicates the excretory function of the liver. The abnormal functional effects produced by CCl<sub>4</sub> are easily demonstrated by the retention of BSP. Liver slices kept in ice cold phosphate buffer (0.2 M) at pH 7.4 were incubated in media (KCl: 10 mM, MgSO<sub>4</sub>: 1 mM, NaCl: 1 mM in phosphate buffer) containing 30 μg BSP/ml at 38°C. An aliquot of reaction mixture was analyzed after 10, 20 and 30 minutes to determine the concentration of BSP in the media at 580 nm [34].

**Statistical analysis**

All data were presented as means ± SEM. Experimental data was analysed using one-way ANOVA followed by Student’s *t*-test to compare the difference between the control and treated values. *P* value <0.05 were considered significant. Graph Pad Prism Version 3.02 was used for statistical calculations.

**RESULTS**

**Thiopentone-induced sleeping time**

*W. tinctoria* triterpenoidal fraction showed statistically extremely-significant (*p*<0.001) hepatoprotective activity (94.06%) by reducing the sleeping time to 20.95 ± 1.87 min compared to 65.72 ± 2.43 min of negative control at 1000 mg/kg dose (Table 1)
Table 1. Hepatoprotective effect of *W. tinctoria* triterpenoidal fraction on thiopentone-induced sleeping time against CCl₄-induced liver damage on rats.

<table>
<thead>
<tr>
<th>Treatment (mg/kg, p.o.)</th>
<th>Sleeping time in min.</th>
<th>% Hepatoprotection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>17.06 ± 1.50</td>
<td>---</td>
</tr>
<tr>
<td>CCl₄ (1.5, i.p)</td>
<td>65.72 ± 2.43</td>
<td>---</td>
</tr>
<tr>
<td>Silymerin (20)</td>
<td>20.56 ± 1.08&lt;sup&gt;a&lt;/sup&gt;</td>
<td>94.86</td>
</tr>
<tr>
<td>WTTF (125)</td>
<td>33.58 ± 2.14&lt;sup&gt;a&lt;/sup&gt;</td>
<td>64.00</td>
</tr>
<tr>
<td>WTTF (250)</td>
<td>22.42 ± 2.03&lt;sup&gt;a&lt;/sup&gt;</td>
<td>91.03</td>
</tr>
<tr>
<td>WTTF (400)</td>
<td>20.95 ± 1.87&lt;sup&gt;a&lt;/sup&gt;</td>
<td>94.06</td>
</tr>
</tbody>
</table>

n = 6. Percentage of hepatoprotection was calculated using the equation: \( H = \frac{1 - (T - V)}{C - V} \) × 100. Where \( T \) is mean value of group treated with test drug and \( C \) is mean value of group treated with CCl₄ alone and \( V \) is the mean value of control animals. *p*<0.001 when compared to negative control (CCl₄-treated) group.

Table 2. Effect of *W. tinctoria* triterpenoidal fraction on serum biochemical parameters of CCl₄-treated rats.

<table>
<thead>
<tr>
<th>Treatment (mg/kg, p.o.)</th>
<th>Cholesterol mg/dL</th>
<th>Tri-glyceride mg/dL</th>
<th>Protein gm/dL</th>
<th>Albumin gm/dL</th>
<th>Bilirubin (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle (control)</td>
<td>152.60 ± 3.60</td>
<td>113.50 ± 4.55</td>
<td>8.88 ± 0.34</td>
<td>3.57 ± 0.65</td>
<td>0.75 ± 0.04</td>
</tr>
<tr>
<td>CCl₄ (1.5, i.p)</td>
<td>68.92 ± 3.55</td>
<td>220.05 ± 5.72</td>
<td>5.85 ± 0.40</td>
<td>1.52 ± 0.35</td>
<td>8.36 ± 0.79</td>
</tr>
<tr>
<td>Silymerin (20)</td>
<td>72.57 ± 3.21&lt;sup&gt;ns&lt;/sup&gt;</td>
<td>131.54 ± 4.32c</td>
<td>8.46 ± 0.24a</td>
<td>2.58 ± 0.35ns</td>
<td>0.55 ± 0.02c</td>
</tr>
<tr>
<td>WTTF (125)</td>
<td>81.72 ± 3.08a</td>
<td>200.65 ± 4.25ns</td>
<td>6.52 ± 0.58ns</td>
<td>1.48 ± 0.22ns</td>
<td>5.69 ± 0.62b</td>
</tr>
<tr>
<td>WTTF (250)</td>
<td>104.02 ± 3.61c</td>
<td>148.51 ± 3.06c</td>
<td>6.97 ± 0.18c</td>
<td>1.98 ± 0.44ns</td>
<td>2.92 ± 0.14c</td>
</tr>
<tr>
<td>WTTF (400)</td>
<td>142.62 ± 4.37c</td>
<td>126.12 ± 3.58c</td>
<td>7.61 ± 0.52c</td>
<td>2.52 ± 0.17ns</td>
<td>1.12 ± 0.13c</td>
</tr>
</tbody>
</table>

n = 6. *p*<0.05, *p*<0.01, *p*<0.001 and ns = not significant when compared to negative control (CCl₄-treated) group.

**Effect on Serum biochemical parameters**

Hepatotoxin CCl₄ get converted into CCl₄O⁻ by liver enzymes and attacks the unsaturated fatty acids of cell membrane in presence of oxygen consequently give rise to lipid peroxides which alters the functional integrity of liver mitochondria leading to liver damage. The levels of marker enzymes SGOT, SGPT and ALP were found to be elevated in cytoplasm as well as in blood. Serum triglyceride and bilirubin (total and direct) level elevated, on the other hand serum total protein, albumin and cholesterol level decreased. WTTF treatment significantly (*p*<0.001 & 0.01) decreased SGOT, SGPT and ALP levels of treated animals at all the tested doses compared to negative control group (Fig 1). Triglyceride level was also decreased at 250 and 400 mg/kg dose which is extremely significant (*P*<0.001). WTTF significantly (*p*<0.001 & 0.01) increased cholesterol level of serum at 250 and 400 mg/kg.

Triterpene treatment did not have any significant effect towards normalization of serum protein and albumin level in treated animals. WTTF significantly decreased serum total bilirubin (*P*<0.001) and direct bilirubin (*P*<0.01) at 250 and 400 mg/kg dose (Table 2).

**Estimation of liver free radical scavenging ability**

CCl₄ intoxication reduced superoxide dismutase enzyme level expressed in unit/mg of protein in liver tissue reported in Table 3. WTTF treatment showed significant enhancement ability of SOD only at 400 mg/kg dose. WTTF at 1000 mg/kg dose showed extremely significant (*p*<0.001) reduction in lipidperoxidase and elevation of glutathione.

**Histopathological parameters**

WTTF treatment showed hepatoprotection by reducing the liver weight of CCl₄ intoxicated animals. Liver weight/100 gm of body weight for vehicle control,
negative control, Silymerin and WTTF (1000 mg/kg) were 3.29, 5.18, 3.94 and 4.18 gm respectively (Fig 2).

Liver sections of vehicle control animals indicate normal appearance of hepatic parenchyma. CCl4-treated animals showed degenerative changes, bile duct hyperplasia, zonal necrosis plus extensive diffuse vacuolar degeneration engorged with blood and microvesicular fatty changes in hepatocytes which indicates completely damaged cytoarchitecture of liver. Silymerin-treated animals showed slightly altered hepatic parenchyma with focal necrosis, lobular necrosis, centrolobular necrosis and sinusoidal dilation with slightly altered hepatic parenchyma

WTTF (400 mg/kg) treatment showed sinusoidal dilation with mild focal coagulative necrosis and slightly altered hepatic parenchyma. Histopathological observations and photomicrographs of liver slices were shown in Fig 3.

Viability of liver cells

WTTF treatment at all the tested doses showed extremely significant (P<0.001) hepatoprotection against CCl4 by increasing the viable liver cell count. Silymerin showed 87.89% of viable cell compared to 61.56% of negative control and 92.99% of vehicle control respectively as shown in Table 4. WTTF at 400 mg/kg dose showed 85.05% viable liver cell.

Bromosulphthalein uptake test

Liver slices of WTTF treated animals showed statistically extremely significant (P<0.001) hepatoprotection (78.60%) at 1000 mg/kg dose. It showed 90.33 ± 5.72 μg of BSP uptake per gm of liver tissue compared to 42.11 ± 2.38 μg of CCl4 treated group (Fig 4).

DISCUSSION

Viral hepatitis is a common disease in the world, especially in developing countries. However, there are no effective drugs for the treatment of this disease. In recent years scientists have carried out a considerable amount of research on traditional medicine in an attempt to develop new drugs for hepatitis. Toxic liver injury produced by drugs and chemicals may virtually mimic any form of naturally-occurring liver disease. In fact, any patient presenting with liver disease or unexplained jaundice is thoroughly questioned about history of drug intake or exposure to chemicals. Hepatotoxicity from drugs and chemicals is the commonest form of iatrogenic disease. Cameron and Karunarathe reported liver injury due to oral administration of carbon tetrachloride [35]. CCl4-induced liver damage in experimental animals is a commonly used model for the screening of hepatoprotective drugs. The hepatotoxic effects of CCl4 are largely due to biotransformation by the cytochrome P-450 system to active metabolite, trichloromethyl radical [36]. Covalent binding of the trichloromethyl radical to cell protein is considered the initial step in a chain of events that eventually leads to lipid peroxidation of the cell membrane and endoplasmic reticulum. Lipid peroxidation in turn gives products like malondialdehyde (MDA) that cause damage to the membrane. The peroxidative products induce hypoperfusion of the membrane and finally cytosolic enzymes appear in the blood [37]. This is evidenced by an elevation in the serum marker enzymes namely SGPT, SGOT and ALP.

Estimation of the serum enzymes is a useful quantitative marker of the extent and type of hepatocellular damage. In CCl4 toxicity, liver lesion develops within one-two hours, however late toxic effects may appear after a delay of several hours or two to three days. Liver toxicants cause disturbances in synthesis and metabolism of triglycerides, cholesterol and lipoproteins, thus damaging the basic resource for living cells. The increased triglyceride content in the blood is in correlation with the fatty degeneration of the liver [38]. The lowering of different serum marker enzyme level is a definite indication of hepatoprotective effect.
Hypoalbuminaemia is most frequent in the presence of advanced chronic liver diseases. Hence decline in total protein content can be deemed as a useful index of the severity of cellular dysfunction in chronic liver diseases. The lower level of total proteins recorded in the serum of CCl₄ treated rats reveals the severity of hepatopathy. WTTF treatment did not show any significant effect to attain normal protein content of CCl₄ intoxicated rats. Theses results signify that the WTTF may not have effect on cellular regeneration of macromolecules. The tendency of these enzymes to return towards a near normal level in WTTF treated rats is a clear manifestation of antihepatotoxic effect of \textit{W. tinctoria}.

Hyperbilirubinaemia can result from impaired hepatic uptake of unconjugated bilirubin. Such a situation can occur in generalized liver cell injury. Certain drugs like rifampin and probenecid interfere with the net uptake of bilirubin by the liver cell and may produce a mild unconjugated hyperbilirubinaemia [39]. Both total and direct bilirubin level rise in disease of hepatocytes, obstruction to biliary excretion into deodenum, hemolysis, in defects of hepatic uptake and conjugation of bilirubin pigment such as in Gilbert’s disease. WTTF treatment significantly reduced the elevated serum level of total and direct Bilirubin.

Liver toxicity increases liver weight, as in paracetamol intoxication, fatty changes occur and there is a fall in serum lipids. Avadhoot and Rana and Bhanwara et al. reported this as a parameter in ascertaining the hepatoprotective effect of drugs [40-41]. Animals of negative control group significantly lost their body weight and showed reduced food consumption as compared to control group. WTTF treatment showed a significant reversal towards loss of body weight. These findings suggest that \textit{W. tinctoria} TF administration significantly neutralized the toxic effect of CCl₄ and helped in regeneration of...
Hepatic damage is a measure of activity of hepatic microsomal drug metabolizing enzymes. Intoxicated liver prolongs duration of sleeping time for hexobarbitone, thiopentone, zoxazolamime and pentobarbitone in animals. Thiopentone induced sleeping time in animals with liver intoxication is increased as the enzyme responsible for metabolism of thiopentone is reduced or destroyed [42]. Therefore, protective effect exhibited by W. tinctoria TF may be due to protection of hepatic drug-metabolizing enzymes as evidenced from decrease in thiopentone-induced sleeping in treated animals.

CCl₄ intoxication reduces the number of viable cell as highly reactive CCl₃ radical-induced lipid peroxidation disturbs Ca²⁺ homeostasis and finally results in cell death [37]. WTTF treatment significantly increased the number of viable hepatocytes which may be attributed to the inhibition of toxin induced free radical generation and in turn stabilizing the cell membrane. WTTF significantly increased glutathione and SOD. Increase in glutathione activity indicated that WTTF helps in the restoration of vital molecules such as NAD, cytochrome and glutathione. Restoration of SOD can help in cellular defense mechanism by preventing cell membrane oxidation. WTTF significantly decreased lipid peroxidation. By virtue of this antioxidant activity, the Triterpene fraction preserved the structural integrity of the plasma cellular membrane of the hepatocytes and protected it from breakage by the reactive metabolites produced. WTTF at higher dose have significantly improved the capacity of the damaged liver to take up BSP. This increased uptake of BSP by the liver slices showed it enhanced capacity to excrete the dye from the blood.

The histopathological studies are direct evidence of efficacy of drug as hepatoprotective agent. Simultaneous treatment of WTTF with CCl₄ exhibited less damage to the hepatic cells as compared to the rats treated with CCl₄ alone. Hepatic cells adjoining to intralobular vein show atrophy. Almost negligible damage to a few hepatocytes present in the close vicinity of intralobular vein was observed. Endothelium lining was almost smooth except at one or two places. Hepatocytes showed normal appearance, only some cells showed higher number of vacuoles in the cytoplasm. Although WTTF did not appear to bring a complete reversal of drug-induced injury in the liver but had minimized the effect of CCl₄. The histopathological observations showed a faster regeneration of hepatic cells which seem to suggest the possibility of WTTF being able to condition the hepatic cells to a state of accelerated regeneration, thus decreasing the leakage of SGPT, SGOT and ALP into the circulation [43].

In conclusion, the observed protective effect of W. tinctoria triterpinoideal fraction against hepatotoxins may be attributed to the presence of lupeol and beta-amyrin. The curative action on hepatic injury by the W. tinctoria TF may be due to the presence of active compounds which prevents liver plasma membrane alteration or promote repair of the liver cells. Plants containing Triterpinoideal constituents are reported to have hepatoprotective activity against ethanol-, paracetamol-, cadmium-, ter-butyl hydroperoxide-, galactosamine-, aflatoxin- and carbon tetrachloride-induced hepatotoxicity [4,5]. Hepatoprotective effect of WTTF on liver injury may be due to its free radical scavenger and antioxidant action. Lupeol and alpha- and beta-amyrin had been reported to have hepatoprotective activity against cadmium-induced hepatotoxicity and acetaminophen-induced liver injury which is predominantly attributed to its antioxidant activity [44,45,3]. In brief, this study supports the traditional use of W. Tinctoria bark as an herbal remedy for jaundice and other liver disorders suggesting the feasibility of developing herbal formulation and clinical studies.

ACKNOWLEDGEMENT

This study was supported by the AICTE, New Delhi, by providing National Doctoral Fellowship (Dr. P. Bigoniya) to one of the authors. The authors are thankful to M/S Ranbaxy Laboratories Ltd., Devas (India) for providing the gift sample of silymerin used for the study.

REFERENCES


CURRENT AUTHOR ADDRESSES

P. Bigoniya, Radharaman College of Pharmacy, Ratibad, Bhopal, M.P. India. E-mail: p_bigoniya2@hotmail.com (Corresponding Author)

A. C. Rana, Department of Pharmaceutical Sciences, Dr H. S. Gour University, Sagar- 470003, Madhya Pradesh, India.